Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An announcement from Editas Medicine ( (EDIT) ) is now available.
Editas Medicine has updated the clinical data from its RUBY trial, showcasing promising results for its gene-edited cell medicine, reni-cel, in treating severe sickle cell disease. The trial demonstrated that reni-cel was well-tolerated and effectively increased hemoglobin levels, with most patients free from vaso-occlusive events. This highlights the potential of reni-cel as a transformative treatment option, offering hope for sustained improvements in patients’ quality of life.
For an in-depth examination of EDIT stock, go to TipRanks’ Stock Analysis page.
